Loading…
Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist
Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic...
Saved in:
Published in: | Angewandte Chemie International Edition 2023-11, Vol.62 (48), p.e202312897-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13 |
---|---|
cites | cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13 |
container_end_page | n/a |
container_issue | 48 |
container_start_page | e202312897 |
container_title | Angewandte Chemie International Edition |
container_volume | 62 |
creator | Lv, Mengdi Zheng, Yue Wu, Jian Shen, Zhengqi Guo, Binglian Hu, Guojing Huang, Yuanlei Zhao, Jingyue Qian, Yong Su, Zhi Wu, Chao Xue, Xuling Liu, Hong‐Ke Mao, Zong‐Wan |
description | Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs).
A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy. |
doi_str_mv | 10.1002/anie.202312897 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2877388932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2877388932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhq0KVD7aa4_IEpdesvgjiZ3jdrVLV0JwoD1Hjj3ZGhJ7aydUufET-hv5JfVqKUhcOM2M9Myj0bwIfaFkRglhF8pZmDHCOGWyEh_QMS0YzbgQ_CD1OeeZkAU9Qicx3iVeSlJ-REdcSE6ooMcIlg_-3roNXkEIfjv4aCNuJnw7OQgbGwer8dL9Uk5DD27AvsUKLybd-W0albHgpg6vgzV27J8e_36DYeysw-u-Hx3g-ca7JPmEDlvVRfj8XE_Rz9Xyx-J7dnVzuV7MrzKdUy6ylgtTNkTlVbquyQvJdEkNaSsC0kgwpWlUaaQw0nBNSlaRnOaMcC0KzShQfoq-7r3b4H-PEIe6t1FD1ykHfow1k-kxUlacJfT8DXrnx-DSdYmqaFXwQuyEsz2lg48xQFtvg-1VmGpK6l0A9S6A-iWAtHD2rB2bHswL_v_jCaj2wB_bwfSOrp5fr5ev8n87BZMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891953571</pqid></control><display><type>article</type><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><source>Wiley</source><creator>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</creator><creatorcontrib>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</creatorcontrib><description>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs).
A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</description><edition>International ed. in English</edition><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.202312897</identifier><identifier>PMID: 37830171</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Anticancer properties ; Antitumor activity ; Apoptosis ; Cell death ; Cyclopentadienyl Ligands ; Cytotoxicity ; Ferroptosis ; Glutathione ; Glutathione peroxidase ; Homeostasis ; Immune response ; Immune system ; Immunochemotherapy ; Immunogenicity ; Immunoregulation ; Iridium ; Iridium - pharmacology ; Iridium Complexes ; Iron ; Iron - metabolism ; Lipid peroxidation ; Lipids ; Lymphocytes ; Lymphocytes T ; Natural products ; Nonferrous metals ; Peroxidase ; Peroxidation ; Phosphatidylinositol 3-Kinases ; Synergistic Strategy ; TOR protein ; Vaccination</subject><ispartof>Angewandte Chemie International Edition, 2023-11, Vol.62 (48), p.e202312897-n/a</ispartof><rights>2023 Wiley‐VCH GmbH</rights><rights>2023 Wiley-VCH GmbH.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</citedby><cites>FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</cites><orcidid>0000-0003-4720-7378 ; 0000-0002-0968-6518 ; 0000-0001-7131-1154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37830171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lv, Mengdi</creatorcontrib><creatorcontrib>Zheng, Yue</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Shen, Zhengqi</creatorcontrib><creatorcontrib>Guo, Binglian</creatorcontrib><creatorcontrib>Hu, Guojing</creatorcontrib><creatorcontrib>Huang, Yuanlei</creatorcontrib><creatorcontrib>Zhao, Jingyue</creatorcontrib><creatorcontrib>Qian, Yong</creatorcontrib><creatorcontrib>Su, Zhi</creatorcontrib><creatorcontrib>Wu, Chao</creatorcontrib><creatorcontrib>Xue, Xuling</creatorcontrib><creatorcontrib>Liu, Hong‐Ke</creatorcontrib><creatorcontrib>Mao, Zong‐Wan</creatorcontrib><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><title>Angewandte Chemie International Edition</title><addtitle>Angew Chem Int Ed Engl</addtitle><description>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs).
A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Apoptosis</subject><subject>Cell death</subject><subject>Cyclopentadienyl Ligands</subject><subject>Cytotoxicity</subject><subject>Ferroptosis</subject><subject>Glutathione</subject><subject>Glutathione peroxidase</subject><subject>Homeostasis</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunochemotherapy</subject><subject>Immunogenicity</subject><subject>Immunoregulation</subject><subject>Iridium</subject><subject>Iridium - pharmacology</subject><subject>Iridium Complexes</subject><subject>Iron</subject><subject>Iron - metabolism</subject><subject>Lipid peroxidation</subject><subject>Lipids</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Natural products</subject><subject>Nonferrous metals</subject><subject>Peroxidase</subject><subject>Peroxidation</subject><subject>Phosphatidylinositol 3-Kinases</subject><subject>Synergistic Strategy</subject><subject>TOR protein</subject><subject>Vaccination</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkU1P3DAQhq0KVD7aa4_IEpdesvgjiZ3jdrVLV0JwoD1Hjj3ZGhJ7aydUufET-hv5JfVqKUhcOM2M9Myj0bwIfaFkRglhF8pZmDHCOGWyEh_QMS0YzbgQ_CD1OeeZkAU9Qicx3iVeSlJ-REdcSE6ooMcIlg_-3roNXkEIfjv4aCNuJnw7OQgbGwer8dL9Uk5DD27AvsUKLybd-W0albHgpg6vgzV27J8e_36DYeysw-u-Hx3g-ca7JPmEDlvVRfj8XE_Rz9Xyx-J7dnVzuV7MrzKdUy6ylgtTNkTlVbquyQvJdEkNaSsC0kgwpWlUaaQw0nBNSlaRnOaMcC0KzShQfoq-7r3b4H-PEIe6t1FD1ykHfow1k-kxUlacJfT8DXrnx-DSdYmqaFXwQuyEsz2lg48xQFtvg-1VmGpK6l0A9S6A-iWAtHD2rB2bHswL_v_jCaj2wB_bwfSOrp5fr5ev8n87BZMg</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Lv, Mengdi</creator><creator>Zheng, Yue</creator><creator>Wu, Jian</creator><creator>Shen, Zhengqi</creator><creator>Guo, Binglian</creator><creator>Hu, Guojing</creator><creator>Huang, Yuanlei</creator><creator>Zhao, Jingyue</creator><creator>Qian, Yong</creator><creator>Su, Zhi</creator><creator>Wu, Chao</creator><creator>Xue, Xuling</creator><creator>Liu, Hong‐Ke</creator><creator>Mao, Zong‐Wan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4720-7378</orcidid><orcidid>https://orcid.org/0000-0002-0968-6518</orcidid><orcidid>https://orcid.org/0000-0001-7131-1154</orcidid></search><sort><creationdate>20231127</creationdate><title>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</title><author>Lv, Mengdi ; Zheng, Yue ; Wu, Jian ; Shen, Zhengqi ; Guo, Binglian ; Hu, Guojing ; Huang, Yuanlei ; Zhao, Jingyue ; Qian, Yong ; Su, Zhi ; Wu, Chao ; Xue, Xuling ; Liu, Hong‐Ke ; Mao, Zong‐Wan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Apoptosis</topic><topic>Cell death</topic><topic>Cyclopentadienyl Ligands</topic><topic>Cytotoxicity</topic><topic>Ferroptosis</topic><topic>Glutathione</topic><topic>Glutathione peroxidase</topic><topic>Homeostasis</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunochemotherapy</topic><topic>Immunogenicity</topic><topic>Immunoregulation</topic><topic>Iridium</topic><topic>Iridium - pharmacology</topic><topic>Iridium Complexes</topic><topic>Iron</topic><topic>Iron - metabolism</topic><topic>Lipid peroxidation</topic><topic>Lipids</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Natural products</topic><topic>Nonferrous metals</topic><topic>Peroxidase</topic><topic>Peroxidation</topic><topic>Phosphatidylinositol 3-Kinases</topic><topic>Synergistic Strategy</topic><topic>TOR protein</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lv, Mengdi</creatorcontrib><creatorcontrib>Zheng, Yue</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Shen, Zhengqi</creatorcontrib><creatorcontrib>Guo, Binglian</creatorcontrib><creatorcontrib>Hu, Guojing</creatorcontrib><creatorcontrib>Huang, Yuanlei</creatorcontrib><creatorcontrib>Zhao, Jingyue</creatorcontrib><creatorcontrib>Qian, Yong</creatorcontrib><creatorcontrib>Su, Zhi</creatorcontrib><creatorcontrib>Wu, Chao</creatorcontrib><creatorcontrib>Xue, Xuling</creatorcontrib><creatorcontrib>Liu, Hong‐Ke</creatorcontrib><creatorcontrib>Mao, Zong‐Wan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lv, Mengdi</au><au>Zheng, Yue</au><au>Wu, Jian</au><au>Shen, Zhengqi</au><au>Guo, Binglian</au><au>Hu, Guojing</au><au>Huang, Yuanlei</au><au>Zhao, Jingyue</au><au>Qian, Yong</au><au>Su, Zhi</au><au>Wu, Chao</au><au>Xue, Xuling</au><au>Liu, Hong‐Ke</au><au>Mao, Zong‐Wan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angew Chem Int Ed Engl</addtitle><date>2023-11-27</date><risdate>2023</risdate><volume>62</volume><issue>48</issue><spage>e202312897</spage><epage>n/a</epage><pages>e202312897-n/a</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Ferroptosis is a form of programmed cell death driven by iron‐dependent lipid peroxidation (LPO) with the potential for antitumor immunity activation. In this study, a nonferrous cyclopentadienyl metal‐based ferroptosis inducer [Ir(Cp*)(Bet)Cl]Cl (Ir‐Bet) was developed by a metal‐ligand synergistic enhancement (MLSE) strategy involving the reaction of [Ir(Cp*)Cl]2Cl2 with the natural product Betulin. The fusion of Betulin with iridium cyclopentadienyl (Ir‐Cp*) species as Ir‐Bet not only tremendously enhanced the antiproliferative activity toward cancer cells, but also activated ferritinophagy for iron homeostasis regulation by PI3K/Akt/mTOR cascade inhibition with a lower dosage of Betulin, and then evoked an immune response by nuclear factor kappa‐B (NF‐κB) activation of Ir‐Cp* species. Further immunogenic cell death (ICD) occurred by remarkable ferroptosis through glutathione (GSH) depletion, glutathione peroxidase 4 (GPX4) deactivation and ferritinophagy. An in vivo vaccination experiment demonstrated desirable antitumor and immunogenic effects of Ir‐Bet by increasing the ratio of cytotoxic T cells (CTLs)/regulatory T cells (Tregs).
A metal‐ligand synergistic enhancement (MLSE) strategy was used to develop an immune agonist Ir‐Bet composed of an iridium complex fused with the natural product Betulin, which induced ferritinophagy‐enhanced ferroptosis to activate antitumor immunity. The MLSE strategy not only promotes effective ferroptosis and immunogenic cell death (ICD), but also provides a new mechanism of action for metal‐based anticancer complexes for cancer therapy.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37830171</pmid><doi>10.1002/anie.202312897</doi><tpages>12</tpages><edition>International ed. in English</edition><orcidid>https://orcid.org/0000-0003-4720-7378</orcidid><orcidid>https://orcid.org/0000-0002-0968-6518</orcidid><orcidid>https://orcid.org/0000-0001-7131-1154</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1433-7851 |
ispartof | Angewandte Chemie International Edition, 2023-11, Vol.62 (48), p.e202312897-n/a |
issn | 1433-7851 1521-3773 |
language | eng |
recordid | cdi_proquest_miscellaneous_2877388932 |
source | Wiley |
subjects | 1-Phosphatidylinositol 3-kinase AKT protein Anticancer properties Antitumor activity Apoptosis Cell death Cyclopentadienyl Ligands Cytotoxicity Ferroptosis Glutathione Glutathione peroxidase Homeostasis Immune response Immune system Immunochemotherapy Immunogenicity Immunoregulation Iridium Iridium - pharmacology Iridium Complexes Iron Iron - metabolism Lipid peroxidation Lipids Lymphocytes Lymphocytes T Natural products Nonferrous metals Peroxidase Peroxidation Phosphatidylinositol 3-Kinases Synergistic Strategy TOR protein Vaccination |
title | Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evoking%20Ferroptosis%20by%20Synergistic%20Enhancement%20of%20a%20Cyclopentadienyl%20Iridium%E2%80%90Betulin%20Immune%20Agonist&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Lv,%20Mengdi&rft.date=2023-11-27&rft.volume=62&rft.issue=48&rft.spage=e202312897&rft.epage=n/a&rft.pages=e202312897-n/a&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.202312897&rft_dat=%3Cproquest_cross%3E2877388932%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4137-f37d6b0a49301b4582c61d0f90e8d8ed6dba6d87d8d3c06290414203c75c21e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2891953571&rft_id=info:pmid/37830171&rfr_iscdi=true |